Just three out of the 15 requests for extensions of therapeutic indications that the European Medicines Agency’s Committee for Medicinal Products for Human Use considered for adoption at its latest meeting got the okay. No opinions were given on the remaining 12, meaning the CHMP will request supplementary information from the applicants in question.
The three successful applicants were Eli Lilly, Gilead Sciences, and Bristol-Myers Squibb. The products were, respectively, Taltz (ixekizumab), Truvada (emtricitabine/tenofovir...








